⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
globenewswire.com
MESO
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
globenewswire.com
MESO
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
globenewswire.com
FBLG
FATE
MESO
LGVN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
prnewswire.com
MESO
LGVN
LCTX
MNKD
Mesoblast to Host R&D Day on April 8, 2026
globenewswire.com
MESO
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
globenewswire.com
MESO
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
prnewswire.com
FBLG
MESO
LGVN
FATE
Ryoncil® Profits Underpinning Substantial Growth Pipeline
globenewswire.com
MESO
Mesoblast Financial Results and Corporate Update Webcast
globenewswire.com
MESO
Stem Cell Therapy Market to Reach USD 45.2B by 2036 (8.4% CAGR) | U.S., Germany & Japan Lead Growth | Mesenchymal Stem Cells Hold 45% Share -- Future Market Insights
prnewswire.com
MESO
GERN
BCDA
NVS
BMY